Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Inventory (2023 - 2024)

Seres Therapeutics' Change in Inventory history spans 2 years, with the latest figure at $10.4 million for Q3 2024.

  • For Q3 2024, Change in Inventory fell 20.78% year-over-year to $10.4 million; the TTM value through Jun 2025 reached $10.4 million, down 78.08%, while the annual FY2024 figure was $33.8 million, 13.99% up from the prior year.
  • Change in Inventory for Q3 2024 was $10.4 million at Seres Therapeutics, down from $11.0 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $13.2 million in Q3 2023 and bottomed at $5.3 million in Q2 2023.